Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Terminated 2Completed 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4Genitourinary 2Head & Neck 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Squamous Cell Carcinoma of Head and Neck 2Triple Negative Breast Neoplasms 1Solid Tumor, Adult 1Oligoprogressive 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Glioblastoma 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1

Interventions

Carboplatin 235Pemetrexed 214Paclitaxel 160Cisplatin 150pembrolizumab 145Erlotinib Hydrochloride 141Docetaxel 133Gemcitabine 94Bevacizumab 85Nivolumab 72Radiotherapy 62atezolizumab 40Radiosurgery 37Afatinib 37osimertinib 35130-nm albumin-bound paclitaxel 35Cetuximab 34durvalumab 33Ipilimumab 32Gefitinib 31Albumin-Bound Paclitaxel 29Vinorelbine 23Taxes 22Etoposide 20Crizotinib 19Radiation 17Sorafenib 16Cyclophosphamide 16Dexamethasone 15Magnetic Resonance Spectroscopy 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × Carcinoma, Non-Small-Cell Lung × Immune Checkpoint Inhibitors × Clear all
NCT02973789 2026-03-18

Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)

NovoCure Ltd.

Phase 3 Completed
291 enrolled 22 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03313804 2026-03-11

Priming Immunotherapy in Advanced Disease With Radiation

University of Kentucky

Phase 2 Completed
76 enrolled 9 charts
Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung

NCT05846646 2025-10-20

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC

ImmuneSensor Therapeutics Inc.

Phase 2 Terminated
6 enrolled 7 charts
GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell

NCT04639245 2023-08-03

Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer

Fred Hutchinson Cancer Center

Phase 1/2 Terminated
1 enrolled 6 charts
BreastGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡